ALS is a devastating neurodegenerative disease, and while there is currently no cure, ongoing research continues to foster hope for more effective treatments. A key contributor to these efforts is Dr. Kathryn Morelli, an assistant professor in the Department of Neurological Sciences at the University of Vermont’s Larner College of Medicine. Her research focuses on addressing the complex challenges of ALS, building upon her previous work with her postdoctoral mentor, Dr. Gene Yeo. Working closely with Abby Kirch, a PhD student in her lab, Dr. Morelli and her team are dedicated to developing RNA-targeted therapies for ALS, particularly targeting the C9ORF72 mutation, one of the most common genetic causes of the disease. To learn more, please read the full story and the Target ALS Post via the links below.

Read the full story at Target ALS and read the Target ALS Post